Bioavailability

Definition

Bioavailability is the fraction of an administered compound that reaches systemic circulation in its active form. For peptides, bioavailability is a central pharmacological consideration because most peptide sequences are rapidly degraded by gastrointestinal enzymes and have limited membrane permeability when taken orally.

Why Bioavailability Matters in Peptide Research

The route of administration significantly affects a peptide’s bioavailability. Subcutaneous and intravenous injection typically achieve near-complete systemic delivery, while oral peptides face enzymatic degradation and poor absorption across the intestinal epithelium. This is why most research peptides are administered via injection rather than orally.

Researchers use several strategies to improve oral bioavailability, including PEGylation (attaching polyethylene glycol chains), lipidation, cyclisation, and co-formulation with permeation enhancers. Semaglutide is a notable example — its oral formulation (Rybelsus) uses an absorption enhancer (SNAC) to achieve clinically relevant bioavailability despite being a 31-amino-acid peptide.

Factors Affecting Peptide Bioavailability

Key factors include molecular weight, lipophilicity, enzymatic stability, and the presence of modifications such as D-amino acid substitutions or disulphide bridges. Peptides with shorter sequences and protective modifications generally show higher bioavailability. The half-life of a peptide is closely related — compounds with longer half-lives often maintain therapeutic concentrations more effectively.

Related Peptides

Peptide profiles that reference “Bioavailability” in their research content.